Abstracts book from the 2010 iMig Kyoto conference.

The PDF file contains all the abstracts presented in Kyoto (114 pages).

You can search for specific topics by using the search function in your Acrobat Reader or by using CTRL+F (CMD+F on a Mac) in your web browser.

A powerful editorial by Prof. Gilles Paradis on chrysotile asbestos export.

Here is an interesting article by Dr Hassan reporting the results of a phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009.
Mesothelin is expressed on the surface of many different cancer cells, particularly in the epithelioid type of mesothelioma.  Mesothelin provides a target for anti-mesothelin antibodies.  At least 2 treatment strategies are being tested currently, the SS1P (a recombinant immunotoxin with anti-mesothelin Fv linked to a truncated Pseudomonas exotoxin) and the MORAb-009 (a high-affinity monoclonal antibody, a chimera between mouse Fv and human IgG1/k Fc).  The MORAb-009 may …

I wish to send greetings to all those visiting the iMig website. As the new President of this international organization, I welcome feedback, participation, and communication about iMig. Please send your ideas and suggestions to me via this website, using the Forum or feedback features.
Our interest is in understanding mesothelioma and how that knowledge will improve care of patients with mesothelioma. This website can function to keep us in contact from around the world. It can also serve as a marketplace of ideas.
We hope to …